Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

330
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
330
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

203
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hantavirus on a Nature Cruise and the Risk of a Pandemic.

JAMA internal medicine·2026
Same author

Enteric populations of <i>Escherichia coli</i> are likely to be resistant to phages due to O antigen expression.

mSphere·2026
Same author

Bacteriophage Heteroresistance as a Cause of Treatment Failure in Urinary Tract Infections.

bioRxiv : the preprint server for biology·2026
Same author

Carbapenemase-producing carbapenem-resistant Enterobacterales in surgical intensive care unit patients in a tertiary hospital in India.

Nature communications·2026
Same author

Assessment of TIMP1, Transgelin-2, and Procalcitonin as Protein Biomarkers for Diagnosis and Prognosis of Bloodstream Infection in a Critically Ill Cohort.

The journal of applied laboratory medicine·2026
Same author

Genomic surveillance of human metapneumovirus in the United States, 2010-2025.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: Sep 11, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K

Microbiome Therapeutics for Clostridioides difficile Infection.

Christine W Lucky1, Brendan J Kelly1, Jennie H Kwon2

  • 1Division of Infectious Diseases, Department of Medicine, Rush University, 600 South Paulina Street, Armour Academic Center, Suite 143, Chicago, IL 60612, USA.

Infectious Disease Clinics of North America
|August 12, 2025
PubMed
Summary

Microbiota-based therapies, such as fecal microbiota transplant, are increasingly used for recurrent Clostridioides difficile infection (rCDI). This review examines the efficacy and unique features of various microbiota products for rCDI treatment.

Keywords:
Clostridioides difficile infectionFecal microbiota productsFecal microbiota transplantLive biotherapeutic productsMicrobiomeRecurrent C difficile

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Related Experiment Videos

Last Updated: Sep 11, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Area of Science:

  • Microbiology
  • Gastroenterology
  • Infectious Diseases

Background:

  • Clostridioides difficile infection (CDI) poses a significant health challenge, especially recurrent CDI (rCDI).
  • Microbiota-based therapies have emerged as a promising treatment strategy for rCDI.
  • Understanding the different types and efficacy of these therapies is crucial.

Purpose of the Study:

  • To review the current landscape of microbiota-based therapies for Clostridioides difficile infection.
  • To present efficacy data for fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products in treating rCDI.
  • To highlight the distinct characteristics of each therapeutic approach.

Main Methods:

  • Literature review of clinical studies and product information.
  • Analysis of efficacy data for various microbiota-based interventions.
  • Comparative assessment of different therapeutic modalities.

Main Results:

  • Fecal microbiota transplant, fecal microbiota products, and live biotherapeutic products show promise in treating rCDI.
  • Efficacy data varies across different microbiota-based therapies.
  • Each product type possesses unique attributes influencing its clinical application.

Conclusions:

  • Microbiota-based therapies represent a significant advancement in managing recurrent Clostridioides difficile infection.
  • The choice of therapy depends on specific patient factors and product characteristics.
  • Further research may elucidate optimal strategies for utilizing these novel treatments.